AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|
22.5 C
New York
Wednesday, September 9, 2026

Tag: autoimmune

newssourceFORcompanyinformationcontent1releasesmarket

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

China’s Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

China’s Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAutoimmune

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers